W
WAVEMAN · COMPANY
TNXP · Tonix Pharmaceuticals Holding Corp.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

TNXP

Tonix Pharmaceuticals Holding Corp.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001430306
CLUSTER · 4 INSIDERSC-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$458.8K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
4
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
79
13F, latest reported quarter
REVENUE GROWTH
+29.8%
XBRL, annual
NET MARGIN
-946.2%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$458.8K over 180 days
+$172.3K over 90 days
more than 84% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
79 funds added or opened last quarter
more than 57% of Pharma & Biotech
REVENUE
+29.8% year over year
more than 74% of Pharma & Biotech
MARGIN
-946.2% net margin
below 88% of Pharma & Biotech
BUYBACKS
$13.8M repurchased, FY to 2025-12-31
below 66% of Pharma & Biotech
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
4 insiders independently bought a net $458.8K — no planned sales are queued against it.
79 funds added or opened positions in the latest 13F quarter, of 103 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -52.5%
-52.5%12M
-66%-39%-13%+13%2025-092025-102025-122026-032026-052026-072026-09 2026-03-18 · LEDERMAN SETH bought $223.3K2026-03-31 · LEDERMAN SETH bought $63.1K2026-06-09 · LEDERMAN SETH bought $58.9K2026-06-08 · Stillwell Richard Newcomb bought $58.2K2026-08-27 · LEDERMAN SETH bought $27.6K2026-06-12 · Taylor Carolyn E. bought $14.9K2026-08-20 · BAGGER RICHARD H bought $12.6K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
4 insiders reported buying shares.
The record shows a net $458.8K bought by insiders over 180 days, 79 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Tonix Pharmaceuticals Holding Corp. insiders bought a net $458.8K of stock across 13 Form 4 purchases and sales, with 4 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
LEDERMAN SETH
Chief Executive Officer
BUY
2026-08-27
2,000.0
$27.6K
BAGGER RICHARD H
Director
BUY
2026-08-20
1,000.0
$12.6K
Taylor Carolyn E.
Director
BUY
2026-06-12
1,415.0
$14.9K
LEDERMAN SETH
Chief Executive Officer
BUY
2026-06-09
5,000.0
$58.9K
Stillwell Richard Newcomb
Director
BUY
2026-06-08
5,000.0
$58.2K
13 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 8 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
1,398,041.0 sh
$17.8M
Point72 Asset Management, L.P.
1,166,752.0 sh
$14.9M
MILLENNIUM MANAGEMENT LLC
966,932.0 sh
$12.3M
AQR CAPITAL MANAGEMENT LLC
882,595.0 sh
$11.3M
VANGUARD CAPITAL MANAGEMENT LLC
691,895.0 sh
$8.8M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
iShares Micro-Cap ETF
$470.4K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$33.2K POSITION · AS OF 2026-03-31
0.0%
iShares Russell 2000 Value ETF
$1.6M POSITION · AS OF 2026-03-31
0.0%
Fidelity Small Cap Value Index Fund
$230.4K POSITION · AS OF 2026-03-31
0.0%
PD Small-Cap Value Index Portfolio
$14.8K POSITION · AS OF 2026-03-31
0.0%
VANGUARD RUSSELL 2000 VALUE INDEX FUND
$118.1K POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · Seth Lederman
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$2.9M
$4.6M
$1.2M
2024
$1.8M
$1.1M
$886.7K
2023
$2.1M
$647.0K
$928.5K
-99%
2022
$4.6M
-$711.5K
$1.4M
-97%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$13.1M$10.1M$7.8M
OPERATING INCOME$-125.7M$-136.7M$-118.4M$-112.1M
NET INCOME$-124.0M$-130.0M$-116.7M$-110.2M
EPS (DILUTED)-14.57-176.60-14,720.25-20.01
OPERATING CASH FLOW$-99.8M$-60.9M$-102.0M$-98.1M
CASH$207.6M$98.8M$24.9M$120.2M
LONG-TERM DEBT$4.7M$6.6M
BUYBACKS$13.8M$14.0M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →